Tanveer Tabish
BSc, MSc, PhD
Research fellow
Cardiovascular and Redox Nanomedicine
OVERVIEW
We orchestrate the development of next-generation functional biomaterials by synergising principles from materials science, chemical biology and biomedical engineering. We specialise in the rational design and chemical functionalisation of avant-garde nanostructures for targeted drug delivery, bioimaging and real-time sensing. A paramount focus lies in fabricating nitric oxide releasing nanomedicines for cardiovascular regeneration, with an emphasis on creating intelligent delivery systems capable of navigating complex biological environments, responding to pathophysiological stimuli and restoring homeostatic function.
CARDIOVASCULAR NANOTHERAPEUTICS
The cellular environment exists in a delicate equilibrium between reducing and oxidising conditions, characterised by the lack of oxygen and hydrogen-rich molecules. This redox balance governs crucial processes from metabolic regulation to cellular signaling and its disruption underpins the pathogenesis of cardiovascular diseases (CVDs). Nitric oxide (NO), a pivotal redox-active mediator, sits at the heart of this paradigm, modulating vascular homeostasis, mitochondrial function and inflammatory cascades. Yet, its therapeutic potential remains constrained by challenges in spatiotemporal delivery and targeted bioactivity. Our work confronts this unmet clinical challenge through an innovative nanomedicine framework, redefining how NO-based therapeutics are engineered. Our research interrogates how endogenous and exogenous NO can be harnessed to treat and prevent CVDs with unprecedented precision. We develop redox-responsive nanodrug excipients capable of navigating the biochemical gradients of cardiovascular system, using pH-selective permeabilities to guide cargo (e.g., NO-releasing materials and NO donors) to subcellular targets in CVD.
In parallel, we are developing advanced synthetic platforms for the real-time imaging of NO at subcellular resolution, illuminating how NO fluxes relate to mitochondrial dysfunction, oxidative stress and endothelial pathology.
One of our flagship efforts involves the design and fabrication of next-generation cardiovascular implants for controlled, sustained and stimulus-responsive therapeutic action. These innovations are pursued in close collaboration with engineers, chemists, pharmacists and clinicians to bridge the gap between fundamental redox biology and translational cardiovascular therapeutics.